AR040406A1 - Antagonistas de histamina h3 de benzimidazolona - Google Patents
Antagonistas de histamina h3 de benzimidazolonaInfo
- Publication number
- AR040406A1 AR040406A1 AR20030101341A ARP030101341A AR040406A1 AR 040406 A1 AR040406 A1 AR 040406A1 AR 20030101341 A AR20030101341 A AR 20030101341A AR P030101341 A ARP030101341 A AR P030101341A AR 040406 A1 AR040406 A1 AR 040406A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently selected
- aryl
- group
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
También se describen composiciones farmacéuticas que comprenden los compuestos de la fórmula (1). Asimismo se describen métodos para el tratamiento de varias enfermedades o trastornos, tales como por ejemplo la alergia, afecciones de las vías respiratorias inducidas por alergia, y congestión (por ejemplo, congestión nasal) usando los compuestos de la fórmula (1). Asimismo se describen métodos para el tratar varias enfermedades o trastornos, tales como por ejemplo la alergia, afecciones de las vías respiratorias inducidas por alergia, y congestión (por ejemplo, congestión nasal) mediante el uso de los compuestos de fórmula (1) en combinación con un antagonista de H1. Reivindicación 1: Un compuesto que está representado por la fórmula estructural (1) o una sal o solvato de los mismos farmacéuticamente aceptable, en los cuales: la línea de puntos representa un doble enlace opcional; a es 0 a 3; b es 0 a 3; n es 1, 2 o 3; p es 1, 2 o 3 con la condición de que cuando M2 es N, entonces p no es 1; r es 1, 2, o 3 con la condición de que cuando r es 2 o 3, entonces M2 es C(R3) y p es 2 o 3; A es un enlace o alquileno C1-6; M1 es C(R3) o N; M2 es C (R3) o N; Y es -C(=O)-, -C(=S)-, -(CH2)q-, -NR4C(=O)-, -C(=O)NR4-, -C(=O)CH2-, -CH2(C=O)-, -SO1-2-, -NH-C(=N-CN)- o -C(=N-CN)-NH-; con la condición de que cuando M1 es N, I no es -NR4C(=O)- o -NH-C(=N-CN)- ; y cuando M2 es N, Y no es -C(=O)NR4- o -C(=N-CN)-NH- ; q es 1 a 5, con la condición de que cuando M1 y M2 son ambos N, q no es 1; Z es un enlace, alquileno C1-6, alquenileno C1-6, -C(=O)-, -CH(CN)-, o -CH2-C(=O)NR4-; R1 es un resto seleccionado del grupo de fórmulas (2); k es 0, 1, 2, 3 o 4; k1 es 0, 1, 2 o 3; k2 es 0, 1 o 2; R es H, alquilo C1-6, hidroxialquilo C2-6-, haloalquilo C1-6-, haloalcoxi C1-6-alquilo C1-6-, R29-O-C(O)-alquilo C1-6-, alcoxi C1-6-alquilo C1-6-, N (R30)(R31)-alquilo C1-6-, alcoxi C1-6-alcoxi C1-6-alquilo C1-6-, R32-arilo, R32-arilalquilo C1-6-, R32-ariloxialquilo C1-6-, R32-heteroarilo, R32-heteroarilalquilo C1-6-, cicloalquilo C3-6, cicloalquil C3-6 alquilo C1-6-, N(R30)(R31)-C(O)-alquilo C1-6-, o heterocicloalquilalquilo C1-6-; R2 es un anillo heteroarilo de seis miembros que tiene 1 o 2 heteroátomos independientemente seleccionados entre N o N-O, siendo los átomos de anillo remanentes carbono; un anillo heteroarilo de cinco miembros que tiene 1, 2, 3 o 4 heteroátomos independientemente seleccionados entre N, O o S, siendo el resto de los anillos carbono; R32-quinolilo ; R32-arilo; heterocicloalquilo ; cicloalquilo C3-6; alquilo C1-6; hidrógeno; o de fórmulas (3), (4) y (5) donde dicho anillo heteroarilo de seis miembros o dicho anillo heteroarilo de cinco miembros está opcionalmente substituido con R6; X es CH o N; Q es un enlace o alquileno C1-6; Q1 es un enlace alquileno C1-6 o -N(R4)-; R3 es H, halógeno, alquilo C1-6, -OH o alcoxi C1-6; R4 está independientemente seleccionado del grupo que consiste en hidrógeno, alquilo C1-6, cicloalquilo C3-6, cicloalquil (C3-6)alquilo C1-6, R33-arilo, R33-arilalquilo C1-6, y R32-heteroarilo ;R5 es hidrogeno, alquilo C1-6, -C(O)R20, -C(O)2R20, -C(O)N(R20)2 o alquilo C1-6 -SO2-; o R4 y R5, conjuntamente con el nitrógeno al cual están unidos, forman un anillo azetidinilo, pirrolidinilo, piperidinilo, piperazinilo o morfolinilo; R6 representa de1 a 3 substituyentes independientemente seleccionados del grupo que consiste en -OH, halógeno, alquilo C1-6-, alcoxi C1-6, alquil C1-6tio, -CF3, -NR4R5, NO2, -CO2R4, -CON(R4)2, -CH2-NR4R5, -CN, o de fórmulas (6), (7) y (8), o 2 substituyentes R6 conjuntamente en el mismo carbono son =O; R12 está independientemente seleccionado del grupo que consiste en alquilo C1-6, hidroxi, alcoxi C1-6, o flúor, con la condición de que cuando R12 es hidroxi o flúor, entonces R12 no está unido a un carbono adyacente a un nitrógeno; o dos substituyentes R12 conjuntamente forman un puente alquilo C1 a C2 de un carbono de anillo a otro carbono de anillo no adyacente; o R12 es =O; R13 está independientemente seleccionado del grupo que consiste en alquilo C1-6, hidroxi, alcoxi C1-6, o flúor, con la condición de que cuando R13 es hidroxi o flúor entonces R13 no están unido a un carbono adyacente a un nitrógeno; o dos substituyentes R13 conjuntamente forman un puente alquilo C1 a C2 de un carbono de anillo a otro carbono de anillo no adyacente; o R13 es =O; R20 está independientemente seleccionado del grupo que consiste en hidrogeno, alquilo C1-6, o arilo, donde dicho grupo arilo está opcionalmente substituido con 1 a 3 grupos independientemente seleccionados de halógeno, -CF3, -OCF3, hidroxi, o metoxi; o cuando dos grupos R20 están presentes, dichos dos grupos R20 tomados conjuntamente con el nitrógeno al cual están unidos pueden formar un anillo heterocíclico de cinco o seis miembros; R22 es alquilo C1-6, R34-arilo o heterocicloalquilo; R24 es H, alquilo C1-6, -SO2R22 o R34-arilo; R25 está independientemente seleccionado del grupo que consiste en alquilo C1-6, -CN, -NO2, halógeno, -CF3, -OH, alcoxi C1-6, alquil C1-6-C(O)-, aril-C(O)-, N(R4)(R5)-C(O)-, N(R4)(R5)-S(O)1-2-, halo-alquilo C1-6- o halo-alcoxi C1-6-alquilo C1-6-; R29 es H, alquilo C1-6, R35-arilo o R35-arilalquilo C1-6-; R30 es H, alquilo C1-6 -, R35-arilo o R35-arilalquilo C1-6-; R31 es H, alquilo C1-6-, R35-arilo, R35-arilalquilo C1-6 -, alquilo C1-6-C(O)-, R35- aril-C(O)-, N(R4)(R5)-C(O)-, alquilo C1-6-S(O)2- o R35-aril-S(O)2-; o R30 y R31 conjuntamente son -(CH2)4-5-, -(CH2)2-O-(CH2)2- o -(CH2)2-N(R29)-(CH2)2- y forman un anillo con el nitrógeno al cual están unidos; R32 representa de 1 a 3 substituyentes independientemente seleccionados del grupo que consiste en H, -OH, halógeno, alquilo C1-6, alcoxi C1-6, -SR22, -CF3, -OCF3, -OCHF2, -NR37R38, -NO2, -CO2R37, -CON(R37)2, -S(O)2R22, -S(O)2N(R20)2, -N(R24)S(O)2R22, -CN, hidroxialquilo C1-6- y -OCH2CH2OR22; R33 representa de 1 a 3 substituyentes independientemente seleccionados del grupo que consiste en alquilo C1-6, halógeno, -CN, -NO2, -OCHF2 y -O-alquilo C1-6; R34 representa de 1 a 3 substituyentes independientemente seleccionados del grupo que consiste en H, halógeno, -CF3, -OCF3, -OH y -OCH3; R35 representa de 1 a 3 substituyentes independientemente seleccionados de hidrogeno, halo, alquil C1-6, hidroxi, alcoxi C1-6, fenoxi, -CF3, -N (R36)2, -COOR20 y -NO2; R36 está independientemente seleccionado del grupo que consiste en H y alquilo C1-6; R37 está independientemente seleccionado del grupo que consiste en hidrogeno, alquilo C1-6, cicloalquilo C3-6, cicloalquil C3-6alquilo C1-6, R33-arilo, R33-arilalquilo C1-6, y R32-heteroarilo; y R38 es hidrogeno, alquilo C1-6, -C(O)R20, -C(O)2R20, -C(O)N(R2)2 o alquil C1-6 -SO2-; o R37 y R38, conjuntamente con el nitrógeno al cual están unidos forman un anillo azetidinilo, pirrolidinilo, piperidinilo, piperazinilo o morfolinilo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37346702P | 2002-04-18 | 2002-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR040406A1 true AR040406A1 (es) | 2005-04-06 |
Family
ID=29736058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AR20030101341A AR040406A1 (es) | 2002-04-18 | 2003-04-16 | Antagonistas de histamina h3 de benzimidazolona |
Country Status (17)
Country | Link |
---|---|
US (1) | US7220735B2 (es) |
EP (1) | EP1494671B1 (es) |
JP (2) | JP4563800B2 (es) |
KR (1) | KR20040099449A (es) |
CN (1) | CN100360130C (es) |
AR (1) | AR040406A1 (es) |
AT (1) | ATE529112T1 (es) |
AU (1) | AU2003223631B2 (es) |
CA (1) | CA2482551C (es) |
IL (1) | IL164583A (es) |
MX (1) | MXPA04010172A (es) |
MY (1) | MY132566A (es) |
NZ (1) | NZ535764A (es) |
PE (1) | PE20040464A1 (es) |
TW (1) | TW200305409A (es) |
WO (1) | WO2003103669A1 (es) |
ZA (1) | ZA200407985B (es) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
AR040405A1 (es) * | 2002-04-18 | 2005-04-06 | Schering Corp | Derivados de bencimidazol utiles como antagonistas de histamina h3 |
CA2482551C (en) * | 2002-04-18 | 2009-08-11 | Schering Corporation | 1-(4-piperidinyl) benzimidazolones as histamine h3 antagonists |
PT1556354E (pt) * | 2002-06-28 | 2008-04-17 | Euro Celtique Sa | Derivados de piperazina úteis como agentes terapêuticos para o tratamento da dor |
US7332508B2 (en) * | 2002-12-18 | 2008-02-19 | Novo Nordisk A/S | Substituted homopiperidine, piperidine or pyrrolidine derivatives |
CA2523431A1 (en) | 2003-04-23 | 2004-11-25 | Glaxo Group Limited | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases |
US20050119266A1 (en) * | 2003-10-01 | 2005-06-02 | Yan Shi | Pyrrolidine and piperidine derivatives as factor Xa inhibitors |
WO2005058823A1 (ja) * | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | ウレア誘導体、その製造法及び用途 |
CA2572075A1 (en) | 2004-06-28 | 2006-01-12 | Janssen Pharmaceutica Nv | Hetero isonipecotic modulators of vanilloid vr1 receptor |
TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
JP2008535790A (ja) * | 2005-03-03 | 2008-09-04 | サートリス ファーマシューティカルズ, インコーポレイテッド | サーチュインモジュレーターであるn−フェニルベンズアミド誘導体 |
CN101243072A (zh) * | 2005-06-20 | 2008-08-13 | 先灵公司 | 用作组胺h3拮抗剂的哌啶衍生物 |
CA2609957A1 (en) | 2005-06-20 | 2007-01-04 | Schering Corporation | Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists |
CA2606004A1 (en) * | 2005-08-02 | 2007-02-08 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
EP1910384B1 (en) * | 2005-08-04 | 2012-10-10 | Sirtris Pharmaceuticals, Inc. | Imidazo [2,1-b]thiazole derivatives as sirtuin modulating compounds |
US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US7855289B2 (en) * | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
WO2007035703A1 (en) * | 2005-09-20 | 2007-03-29 | Schering Corporation | 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist |
JP2009521452A (ja) * | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | コレステロール降下剤およびh3受容体アンタゴニスト/逆アゴニストを使用する非アルコール性脂肪性肝疾患の処置 |
JP2009521448A (ja) * | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | ヒスタミンh3アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ |
CA2634847A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Substituted aniline derivatives useful as histamine h3 antagonists |
JP2009521445A (ja) * | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | H3アンタゴニスト/逆アゴニストと食欲抑制剤との組み合わせ |
WO2007130712A1 (en) * | 2006-01-31 | 2007-11-15 | Janssen Pharmaceutica, Nv | Substituted dipiperidine as ccr2 antagonists for the treatment of inflammatory diseases |
US7728031B2 (en) * | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
AR063275A1 (es) * | 2006-10-12 | 2009-01-14 | Epix Delaware Inc | Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2. |
US20100144591A1 (en) * | 2007-03-02 | 2010-06-10 | Schering Corporation | Benzimidazole derivatives and methods of use thereof |
TW200916472A (en) * | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
AU2008319267A1 (en) * | 2007-11-01 | 2009-05-07 | Sirtris Pharmaceuticals, Inc. | Amide derivatives as sirtuin modulators |
JP2011503066A (ja) * | 2007-11-08 | 2011-01-27 | サートリス ファーマシューティカルズ, インコーポレイテッド | 可溶化チアゾロピリジン誘導体 |
CN101925383A (zh) | 2007-12-11 | 2010-12-22 | 赛特帕斯凡德株式会社 | 甲酰胺化合物及其作为趋化因子受体激动剂的应用 |
NZ587202A (en) * | 2008-01-04 | 2013-03-28 | Schabar Res Associates Llc | Methods for measuring a patient response upon administration of a drug and compositions thereof |
EP2376502B1 (en) | 2008-12-19 | 2015-06-17 | GlaxoSmithKline LLC | Thiazolopyridine sirtuin modulating compounds |
KR20130087002A (ko) | 2010-06-04 | 2013-08-05 | 알바니 몰레큘라 리써치, 인크. | 글리신 수송체-1 저해제, 그의 제조 방법 및 그의 용도 |
JP2014114212A (ja) * | 2011-03-29 | 2014-06-26 | Dainippon Sumitomo Pharma Co Ltd | 新規ベンズイミダゾール誘導体 |
WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
WO2016144936A1 (en) | 2015-03-09 | 2016-09-15 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
CA3087886A1 (en) * | 2018-01-19 | 2019-07-25 | Idorsia Pharmaceuticals Ltd | C5a receptor modulators |
CA3134613A1 (en) | 2019-04-02 | 2020-10-08 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
US11318144B2 (en) | 2019-04-12 | 2022-05-03 | LA PharmaTech Inc. | Compositions and methods for treating Alzheimer's disease and Parkinson's disease |
US11938139B2 (en) | 2019-04-12 | 2024-03-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders |
US10639315B1 (en) | 2019-05-21 | 2020-05-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating Alzheimer's disease |
US10898493B2 (en) | 2019-04-12 | 2021-01-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease |
US11744833B2 (en) | 2019-04-12 | 2023-09-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of insomnia |
WO2020222799A1 (en) * | 2019-04-30 | 2020-11-05 | La Pharma Tech Inc. | A method of treating mental, behavioral, cognitive disorders |
US10639314B1 (en) | 2019-04-30 | 2020-05-05 | LA PharmaTech Inc. | Method of treating Alzheimer's disease |
US10966989B2 (en) | 2019-04-12 | 2021-04-06 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
US11690849B2 (en) | 2019-04-12 | 2023-07-04 | LA PharmaTech Inc. | Method of treating dementia |
US11389458B2 (en) | 2019-04-12 | 2022-07-19 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating parkinson's and huntington's disease |
CN110105263A (zh) * | 2019-05-13 | 2019-08-09 | 常州大学 | 一种阿米卡星中间体的合成方法 |
WO2022015784A1 (en) | 2020-07-15 | 2022-01-20 | Schabar Research Associates Llc | Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn |
US11324727B2 (en) | 2020-07-15 | 2022-05-10 | Schabar Research Associates, Llc | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn |
WO2022268935A2 (en) * | 2021-06-23 | 2022-12-29 | F. Hoffmann-La Roche Ag | Novel process |
US11351179B1 (en) | 2021-08-05 | 2022-06-07 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of psychiatric disorders |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0730037B2 (ja) | 1987-03-13 | 1995-04-05 | 第一製薬株式会社 | ピリミジニルプロピオン酸誘導体 |
JP2807577B2 (ja) * | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
JP3859738B2 (ja) * | 1993-05-26 | 2006-12-20 | 大日本住友製薬株式会社 | キナゾリノン誘導体 |
FR2725986B1 (fr) * | 1994-10-21 | 1996-11-29 | Adir | Nouveaux derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US5574044A (en) * | 1994-10-27 | 1996-11-12 | Merck & Co., Inc. | Muscarine antagonists |
AU701127B2 (en) * | 1994-10-27 | 1999-01-21 | Merck & Co., Inc. | Muscarine antagonists |
GB9521781D0 (en) * | 1995-10-24 | 1996-01-03 | Merck Sharp & Dohme | Therapeutic agents |
DK0920425T3 (da) * | 1995-11-17 | 2003-05-26 | Aventis Pharma Inc | Substituerede 4-(1H-benzimidazol-2-yl-amino)piperidiner, der er nyttige til behandling af allergiske sygdomme |
US6211199B1 (en) * | 1995-11-17 | 2001-04-03 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases |
BR9711149A (pt) | 1996-08-16 | 1999-08-17 | Schering Corp | Tratamento de respostas al-rgicas das vias respiratÄrias superiores com uma combina-Æo de antagonistas de receptor de histamina |
US5869479A (en) * | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
DE19952146A1 (de) * | 1999-10-29 | 2001-06-07 | Boehringer Ingelheim Pharma | Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
CN1461303A (zh) * | 2000-09-20 | 2003-12-10 | 先灵公司 | 作为双重组胺h1和h3促效剂或拮抗剂的取代咪唑 |
PE20020507A1 (es) | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
US6849621B2 (en) | 2001-03-13 | 2005-02-01 | Schering Corporation | Piperidine compounds |
EP1386920A4 (en) | 2001-04-20 | 2005-09-14 | Banyu Pharma Co Ltd | DERIVATIVES OF BENZIMIDAZOLONE |
CA2482551C (en) * | 2002-04-18 | 2009-08-11 | Schering Corporation | 1-(4-piperidinyl) benzimidazolones as histamine h3 antagonists |
-
2003
- 2003-04-16 CA CA002482551A patent/CA2482551C/en not_active Expired - Fee Related
- 2003-04-16 US US10/414,943 patent/US7220735B2/en not_active Expired - Fee Related
- 2003-04-16 NZ NZ535764A patent/NZ535764A/en not_active IP Right Cessation
- 2003-04-16 CN CNB038137801A patent/CN100360130C/zh not_active Expired - Fee Related
- 2003-04-16 JP JP2004510788A patent/JP4563800B2/ja not_active Expired - Fee Related
- 2003-04-16 AR AR20030101341A patent/AR040406A1/es unknown
- 2003-04-16 AU AU2003223631A patent/AU2003223631B2/en not_active Ceased
- 2003-04-16 MX MXPA04010172A patent/MXPA04010172A/es active IP Right Grant
- 2003-04-16 WO PCT/US2003/011696 patent/WO2003103669A1/en active Application Filing
- 2003-04-16 KR KR10-2004-7016552A patent/KR20040099449A/ko not_active Application Discontinuation
- 2003-04-16 AT AT03719770T patent/ATE529112T1/de not_active IP Right Cessation
- 2003-04-16 EP EP03719770A patent/EP1494671B1/en not_active Expired - Lifetime
- 2003-04-16 MY MYPI20031425A patent/MY132566A/en unknown
- 2003-04-16 PE PE2003000387A patent/PE20040464A1/es not_active Application Discontinuation
- 2003-04-17 TW TW092108926A patent/TW200305409A/zh unknown
-
2004
- 2004-10-04 ZA ZA200407985A patent/ZA200407985B/xx unknown
- 2004-10-14 IL IL164583A patent/IL164583A/en not_active IP Right Cessation
-
2006
- 2006-03-22 JP JP2006079808A patent/JP2006206603A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ZA200407985B (en) | 2005-10-19 |
CA2482551A1 (en) | 2003-12-18 |
CA2482551C (en) | 2009-08-11 |
JP2006206603A (ja) | 2006-08-10 |
MY132566A (en) | 2007-10-31 |
NZ535764A (en) | 2007-10-26 |
AU2003223631B2 (en) | 2006-07-20 |
JP4563800B2 (ja) | 2010-10-13 |
EP1494671A1 (en) | 2005-01-12 |
EP1494671B1 (en) | 2011-10-19 |
WO2003103669A1 (en) | 2003-12-18 |
AU2003223631A1 (en) | 2003-12-22 |
US20040048843A1 (en) | 2004-03-11 |
TW200305409A (en) | 2003-11-01 |
IL164583A (en) | 2010-05-17 |
JP2005529161A (ja) | 2005-09-29 |
KR20040099449A (ko) | 2004-11-26 |
IL164583A0 (en) | 2005-12-18 |
CN100360130C (zh) | 2008-01-09 |
ATE529112T1 (de) | 2011-11-15 |
US7220735B2 (en) | 2007-05-22 |
PE20040464A1 (es) | 2004-07-24 |
CN1658875A (zh) | 2005-08-24 |
MXPA04010172A (es) | 2005-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR040406A1 (es) | Antagonistas de histamina h3 de benzimidazolona | |
AR040405A1 (es) | Derivados de bencimidazol utiles como antagonistas de histamina h3 | |
AR039718A1 (es) | Derivados de indol utiles como antagonistas de la histamina h3 | |
AR065495A1 (es) | Metodos para usar derivados de bencimidazol para tratar o prevenir dolor, diabetes, complicacion diabetica composiciones. | |
AR035497A1 (es) | Compuestos no-imidazol, composicion farmaceutica que los comprenden y el uso de los mismos para la preparacion de medicamentos | |
AR035440A1 (es) | Compuestos antagonistas del receptor h3, el uso de los mismos solos o en combinacion para la manufactura de medicamentos y composiciones farmaceuticas | |
AR120481A1 (es) | Compuestos útiles como inhibidores de la proteína helios | |
NO20073667L (no) | [4-(heteroaryl) piperazin-1-yl]-(2,5-substituert-fenyl)metanonderivater som glycintransportor 1(GLYT-1)- inhibitorer for behandling av neurologiske og neuropsykiatriske lidelser | |
ES2501544T3 (es) | Agentes antihelmínticos y su uso | |
AR079636A1 (es) | Antagonistas del receptor ccr2 y usos de los mismos | |
AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
DE60110066D1 (de) | Piperidine zur verwendung als orexin rezeptor antagonisten | |
AR057989A1 (es) | Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas | |
AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
PE20030761A1 (es) | Derivados del 7-amino-benzotiazol | |
JP2009537483A5 (es) | ||
PE20180799A1 (es) | Reguladores de nrf2 | |
PE20011059A1 (es) | Carboxamidas de pirimidina de formula (i) y composiciones que las comprenden | |
AR044909A1 (es) | Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia | |
ES2171109A1 (es) | Derivados de 4-fenil-piridina. | |
AR055192A1 (es) | 2-quinolil-oxazoles sustituidos utiles como inhibidores de pde4, composicion farmaceutica en base al compuesto y el uso del compuesto para preparar medicamentos | |
CY1122201T1 (el) | Παραγωγα βενζοδιοξολιου ως αναστολεις φωσφοδιεστερασης | |
WO2003080580A3 (en) | Quinoline derivatives and their use as 5-ht6 ligands | |
NO20071198L (no) | N-(1H-indolyl)-1H-indol-2-karboksamidderivater, deres fremstilling og terapeutiske anvendelse | |
NO20063330L (no) | Amidderivater med en syklopropylaminokarbonylsubstituent som er nyttige som cytokininhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |